Natural MedTech: Why the Psychedelic Opportunity Starts With Manufacturing
Unable to add items
Add to basket failed.
Add to wishlist failed.
Failed to remove from Wish List.
Adding to library failed
Unable to follow podcast
Unable to unfollow podcast
Natural MedTech: Why the Psychedelic Opportunity Starts With Manufacturing
-
Narrated by:
-
By:
In this episode of On the Horizon, Natural MedTech CEO and Co-Founder Luke McFarlane joins WTR healthcare analyst Robert Sassoon and Shawn Severson to discuss the company's biosynthetic psilocybin manufacturing platform and its position within Australia's evolving psychedelic medicine landscape. The conversation covers the authorized prescriber pathway, including adoption trends, treatment costs, regulatory developments, and early insurer engagement. McFarlane walks through NMT's proprietary biosynthesis platform, its competitive advantages in cost and purity, the ongoing Series A raise, and the case for local manufacturing. The episode also explores AI's role in drug development, the importance of wet-lab data, NMT's views on drugs-for-data models, and the company's long-term ambitions within the pharmaceutical
